New combo tested to fight advanced lung cancer after first treatment fails
NCT ID NCT03003468
Summary
This study tested whether adding a new drug called Imprime PGG to an existing immunotherapy (pembrolizumab) could help control advanced lung cancer that had worsened after initial chemotherapy. It involved 35 adults with metastatic non-small cell lung cancer. The research first aimed to find a safe dose of the combination, then to see if it could delay cancer growth longer than expected with pembrolizumab alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana Univeristy Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
-
University of Iowa Hospital and Clinics
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.